Allurion Presents at European Obesity Congress
![Test](/sites/default/files/2024-02/Day%202_Shot%2004_Sheyl_Doctor_2153_0.jpg)
![Day 2_Shot 04_Sheyl_Doctor_2153 (1)1.jpg](/sites/default/files/2023-04/Day%202_Shot%2004_Sheyl_Doctor_2153%20%281%291.jpg)
Allurion Announces Three Scientific Presentations at the European Congress on Obesity, Including Study on Lean Mass Preservation for Sustainable, Healthy Weight Loss
New data demonstrate significant fat mass loss while preserving lean mass
NATICK, Mass. -- May 15th, 2024 – Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced three scientific presentations at the 31st European Congress on Obesity (ECO) held in Venice, Italy, on 12-15 May, 2024.
Presentations include data from a study of 712 patients treated with the Allurion Program, which is anchored by the Allurion Balloon and enhanced by the Virtual Care Suite featuring Allurion’s proprietary behavior change program. This study was conducted at six obesity centers in six countries, and the data showed patients achieved total body weight loss (TBWL) of 14.1% on average at 4 months, 70% of which came from fat mass and only 30% of which came from lean body mass.
“The Allurion Program was designed to monitor both weight loss and lean body mass, facilitate basic changes in behavior that can protect skeletal muscle, and reduce the impact on lean body mass during periods of rapid weight loss,” said Dr. Shantanu Gaur, Founder and CEO of Allurion. “Research shows that preserving lean body mass while losing weight is critical to maintaining metabolic health and achieving positive, sustained outcomes.”
Existing obesity interventions — including anti-obesity medications such as GLP-1s and bariatric surgery — are often not delivered with coaching or behavior change programs designed to protect lean body mass, which can lead to significant reductions in muscle mass. For example, GLP-1s have been shown to lead to approximately 40% lean body mass loss at one year of treatment.1,2
“Maintaining lean body mass in the setting of significant caloric deficit is a challenge. We believe the Allurion Program makes this possible with its body composition monitoring and a personalized program that focuses on outcomes beyond just weight,” said Dr. Ram Chuttani, Chief Medical Officer of Allurion. “We will continue to partner with Allurion Program providers to help them optimize their patient outcomes through our training, support, and digital health platform.”
With more intensive programs, early data indicate that muscle mass loss can be avoided entirely. In a previous similar, but smaller, study of a highly intensive multidisciplinary Allurion Program with weekly follow up, patients achieved 14.6% TBWL at 4 months, and their lean body mass actually increased, with 100% of the weight loss derived from fat mass.3
“These results indicate that the Allurion Program may be more protective of muscle mass during weight loss than alternative methods,” continued Gaur. “I am looking forward to exploring how we can leverage the Allurion Virtual Care Suite and Coach Iris to deliver an even more personalized and intensive coaching program to our patients and potentially eliminate muscle mass loss entirely without significant human intervention.”
Presentations at ECO also include data on the positive impact of a behavior change coaching skills course developed by Allurion and the positive impact of GLP-1s on the Allurion Program.
Details of the presentations are as follows:
Title: Body Composition Changes during the Swallowable, Non-Endoscopic Gastric Balloon Program (SIGBP): Prioritizing Lean Mass Preservation for Sustainable, Healthy Weight Loss
Presenter: Roberta Ienca, M.D., Weight Management Center, Nuova Villa Claudia Clinic
Title: Training HCPs in behavior change coaching skills improves weight loss outcomes of the Swallowable, Non-Endoscopic Gastric Balloon Program
Presenter: Zoe Griffiths, Bsc,. RD, Senior Director Behavioral Medicine, Allurion
Title: The Anti-Obesity Medication Halo Effect: Rising Interest in Medications Drives Increased Awareness and Uptake of Other Medical Obesity Treatments
Presenter: Zoe Griffiths, Bsc,. RD, Senior Director Behavioral Medicine, Allurion
For more information about ECO 2024, please visit: https://eco2024.org/.
Sources: 1. Wilding JPH, Batterham RL, Calanna S, et al. N Engl J Med. 2021;384(11):989-1002. 2. McCrimmon RJ, Catarig AM, Frias JP, et al. Diabetologia. 2020;63(3):473-485. 3. Raftopoulos and Giannakou. Surg for Obes and Rel Dis. 2017;13:1174-1182.
About Allurion
Allurion is dedicated to ending obesity. The Allurion Program is a weight loss platform that features the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-less intragastric balloon for weight loss, and offers access to the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers, Allurion Insights for health care providers featuring the Coach Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor and manage weight loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional. The Allurion Gastric Balloon is an investigational device in the United States.
For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com
Allurion is a trademark of Allurion Technologies, Inc. in the United States and countries around the world.
Forward-Looking Statements
This press release may contain certain forward-looking statements within the meaning of the U.S. federal and state securities laws. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions and include statements regarding the ability of the Allurion Program, including the VCS, to improve patient and clinical outcomes, including outcome improvements over time, the impact of a behavior change coaching skills course, and the impact of gLP-1s on the Allurion Program. Forward-looking statements are predictions, projections and other statements about future events that reflect the current beliefs and assumptions of Allurion’s management based on information currently available to them and, as a result, are subject to risks and uncertainties. Many factors could cause actual future results or developments to differ materially from the forward-looking statements in this communication, including but not limited to (i) the ability of Allurion to obtain and maintain regulatory approvals for and successfully commercialize the Allurion Program, including the Allurion Balloon and the VCS, (ii) the timing of, and results from, our clinical studies and trials, (iii) the evolution of the markets in which Allurion competes, (iv) the ability of Allurion to defend its intellectual property, (v) the impact of the COVID-19 pandemic, the Russia and Ukraine war, and the Israel-Hamas conflict on Allurion’s business, (vi) Allurion’s expectations regarding its market opportunities, including those for the VCS platform, and (vii) the risk of economic downturns and a changing regulatory landscape in the highly competitive industry in which Allurion operates. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Allurion’s Annual Report on Form 10-K filed on March 26, 2024 (as subsequently amended) and other documents filed by Allurion from time to time with the U.S. Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Allurion assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Allurion does not give any assurance that it will achieve its expectations.
###
Global Media:
Cedric Damour
PR Manager
+33 7 84 21 02 20
cdamour@allurion.com
Investors:
Mike Cavanaugh, Investor Relations
ICR Westwicke
(617) 877-9641
mike.cavanaugh@westwicke.com
Allurion Announces Publication of New Data Demonstrating Weight Loss in Adolescents Suffering from Obesity
In a...
Allurion Announces Publication of New Data Demonstrating Continued Weight Loss at One Year On the Allurion...
Allurion Announces the Appointment of Eli Lilly Veteran, Keith Johns, to its Board of Directors
Mr. Johns has...
Allurion Announces Publication of New Data Demonstrating Lean Mass Gains in Patients Experiencing 14% Weight...
Allurion Announces Three Scientific Presentations at the 40th Annual Meeting of the American Society for...
Allurion Announces the Appointment of Ojas A. Buch as Chief Operating Officer
NATICK, Mass. -- June 5, 2024 -- ...
Allurion Announces Expansion of AI Weight Loss Coach to Support Patients on GLP-1s
Company also announces first...
Allurion Announces Three Scientific Presentations at IFSO-European Chapter 2024, Including
First-Ever 3-Year...
Allurion Expands Virtual Care Suite to the United States
Virtual Care Suite (VCS) is now available to license...
Brendan Gibbons Appointed Chief Legal Officer at Allurion Technologies
NATICK, Mass. -- Jan. 29, 2024 -- Alluri...
Somerset NHS Foundation Trust Treats First Patients with Allurion Balloon for Pre-Surgical Weight Loss
Allurion...
Allurion's Virtual Care Suite Digital Platform Accelerates Commercial Expansion With New Strategic...
Allurion Program led to resolution of type 2 diabetes, hypertension, and obstructive sleep apnea in just 4...
New research highlights the positive impact of GLP-1s and other anti-obesity medications on the Allurion...
Allurion’s Digital Platform Gains Traction with Expanded Strategic Partnership
Company also announces addition...
Allurion Completes Enrollment in Pivotal AUDACITY Trial for the Allurion Balloon
AUDACITY trial to support FDA...
Allurion Announces Acceptance of Five Abstracts for Presentation at Obesity Week 2023
Research highlights...
Allurion Featured at the 2023 International Bariatric Club
Oxford University World Congress
Congress convenes...
Allurion Introduces Coach Iris: A 24/7 Generative AI-Powered Weight Loss Coach
Powered by GPT and Fine-Tuned...
Allurion Announces Acceptance of Nine Scientific Presentations at IFSO 2023 World Congress
New data includes...
Allurion Debuts as a Publicly Traded Company on the NYSE
Allurion to commence trading on August 2, 2023 on the...
Allurion Announces New Additions to Board of Directors and Executive Leadership Team
Serial healthcare...
Allurion Presents New Data at the 2023 ASMBS Annual Meeting Demonstrating Mean Weight Reduction of Over 20%
P...
Allurion Announces Collaboration Agreement with Medtronic to Expand Access to AI-Powered Weight Loss Program
...Allurion to Participate in the Jefferies Healthcare Conference
NATICK, Mass. -- May 30, 2023 – Allurion, a...
First Multi-Center Study Combining the Allurion Program with GLP-1 Therapy Presented at the European Congress...
Allurion Presents Findings from Landmark Study Evaluating Fully Remote Weight Loss Coaching Program
Proprietar...
Allurion Announces Premium Tiers for the Virtual Care Suite and Launch of Proprietary “My Daily Action” Bundle...
Allurion Announces Appointment of MIT Distinguished Professor for AI and Health and MacArthur “Genius” Fellow
...Allurion named “Champion Partner” of the World Obesity Federation and official sponsor of World Obesity Day...
Allurion, a Global Leader in Weight Loss Technology, to Become Publicly Listed Through Business Combination...
Allurion Technologies’ training awarded World Obesity Federation SCOPE accreditation
- Allurion’s gold...
Company reports 444% revenue growth from 2018 to 2021 and has also been named as one of MedTech Outlook’s Top...
- The world’s first and only procedureless gastric balloon receives approval from Brazilian Health Regulatory...
New Delhi, 06 Sep 2022:
Allurion, a company dedicated to ending obesity, has launched the Allurion Swallowable...
- Company launches the Allurion Iris™ Artificial Intelligence Platform and introduces Success Predictor, a...
Company announces approval of the Allurion Balloon in Canada, Mexico, Australia, and India where approximately...